Related Experiment Video
Updated: Jul 16, 2025

Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues
Published on: April 7, 2023
NASH Drug Development: Seeing the Light at the End of the Tunnel?
1Wuxi School of Medicine, Jiangnan University Medical Center, Wuxi, Jiangsu, China.
Abstract:
Nonalcoholic steatohepatitis (NASH) is a chronic liver disease affecting a large population worldwide. No clinically approved drugs are available. In this minireview, we discuss the heterogeneous nature of NASH and lack of consensus in outcome measures among clinical trials. We summarize NASH therapeutic targets and candidate drugs. We compare the efficacy of 33 published clinical trials that evaluated noninvasive biomarkers and liver biopsy. Currently, phase II trial results of fibroblast growth factor 21 (FGF21) and phase III trial results of resmetirom and pioglitazone are encouraging.
Related Concept Videos
Drug Discovery: Overview
Preclinical Development: Overview
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Clinical Trials: Overview
Drug Nomenclature
Drug Regulation

